Haemodynamic effects of isoflurane and sevoflurane in pulmonary hypertensive mitral valve stenosis

Basit Öğe Kaydı
dc.authorscopusid6507917538
dc.authorscopusid6603931556
dc.authorscopusid34569135700
dc.authorscopusid55666804700
dc.authorscopusid6602622196
dc.authorscopusid6506222899
dc.contributor.authorKadir But A.
dc.contributor.authorTürköz A.
dc.contributor.authorDurmuş M.
dc.contributor.authorToprak H.I.
dc.contributor.authorÇolak C.
dc.contributor.authorÖzcan Ersoy M.
dc.date.accessioned2024-08-04T20:00:59Z
dc.date.available2024-08-04T20:00:59Z
dc.date.issued2002
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAlthough isoflurane and sevoflurane are widely used in cardiac surgery for their clinical properties, sufficient studies on their cardiovascular and pulmonary effects in mitral stenotic patients with pulmonary hypertension have not been found. Forty patients with mitral stenosis and pulmonary hypertension, who were undergoing mitral valve replacement surgery, were randomly divided into Isoflurane (Gi, n=20) and Sevoflurane (Gs, n=20) groups. After anaesthesia induction, the maintenance of anaesthesia was provided with 1 MAC izoflurane in Gi and 1 MAC sevoflurane in Gs. Hemodynamic measurements, central venous pressure (CVP), mean pulmonary arterial pressure (MPAP), pulmonary capillary wedge pressure (PCWP), cardiac index (CI), pulmonary vascular resistance index (PVRI) and systemic vascular resistance index (SVRI), were performed before anaesthesia induction (t0), after intubation (t1), and just before cardiopulmonary bypass (t2). Heart rates (HR) and mean arterial pressure (MAP) were also determined t0, t1 and t2 as well as during incisron (ti) and sternotomi (ts) In inter-group evaluation, HR were found to be different at t2 (p<0.05). In-group evaluation, there was statistically significant decrease at t2 compared to t0 in Gs. Inter-group evaluation revealed no significant difference in the other hemodynamic measurements. In-group evolution, MAP, MPAP, PCWP and CI decreased at t1 and t2 compared to t0 in both groups, but CVP declined only at t2 compared to t0. As a result, 1 MAC isoflurane and sevoflurane used in mitral stenotic patients with pulmonary hypertension caused a decrease in MAP, MPAP, and CVP, which is not necessary to be corrected and the decrease in CI was clinically acceptable. According to results of the study, both agents have been thought to be convenient to be used in patients with mitral stenosis with pulmonary hypertension.en_US
dc.identifier.endpage197en_US
dc.identifier.issn1300-0578
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-0036698638en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage193en_US
dc.identifier.urihttps://hdl.handle.net/11616/91146
dc.identifier.volume10en_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.relation.ispartofAnestezi Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectIsofluraneen_US
dc.subjectMitral stenosisen_US
dc.subjectPulmonary hypertensionen_US
dc.subjectSevofluraneen_US
dc.titleHaemodynamic effects of isoflurane and sevoflurane in pulmonary hypertensive mitral valve stenosisen_US
dc.title.alternativePulmoner hipertansif mitral kapak darli?inda izofluran ve sevofluran'in hemodinamik etkile?ien_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu